Ascitic complement system in ovarian cancer.
Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo. Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor, CD59 and CD46, and the alternative pathway inhibitors factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.
Bjørge
L
L
Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FIN-00014 Helsinki, Finland. Line.Bjorge@gades.uib.no
Hakulinen
J
J
Vintermyr
O K
OK
Jarva
H
H
Jensen
T S
TS
Iversen
O E
OE
Meri
S
S
D000230:Adenocarcinoma / Q000097:blood / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001201:Ascites / Q000097:blood / Q000503:physiopathology*; D018957:CD59 Antigens / Q000097:blood; D045744:Cell Line, Tumor; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D003165:Complement System Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000503:physiopathology*
D000911:Antibodies, Monoclonal; D018957:CD59 Antigens; D003176:Complement C3; D003181:Complement C4; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D003165:Complement System Proteins
Am J Obstet Gynecol. 1987 Jan;156(1):263-4
10681275
J Clin Oncol. 1994 Jul;12(7):1497-515
8021742
Immunology. 1995 Jul;85(3):495-501
7558140
Int Arch Allergy Appl Immunol. 1984;74(1):63-6
6608501
Br J Cancer. 1997;75(9):1247-55
9155042
Eur J Immunol. 2004 Sep;34(9):2620-9
15307194
Nat Med. 1997 Nov;3(11):1266-70
9359703
Int J Cancer. 1998 Mar 2;75(5):663-70
9495231
Am J Obstet Gynecol. 1988 Jul;159(1):94-8
3394756
Blood. 2000 Jun 15;95(12):3900-8
10845926
Tumori. 1996 Sep-Oct;82(5):473-9
9063527
Hum Pathol. 1996 Dec;27(12):1329-35
8958307
Oncol Rep. 1998 Nov-Dec;5(6):1519-24
9769398
Mol Immunol. 1999 Sep-Oct;36(13-14):929-39
10698347
Gynecol Oncol. 1989 Mar;32(3):350-3
2920956
Am J Clin Oncol. 2001 Dec;24(6):562-5
11801754
Immunol Today. 1999 Dec;20(12):576-82
10562709
Blood. 1997 Sep 15;90(6):2188-95
9310469
Tumour Biol. 1998;19(1):1-11
9422077
Immunology. 1992 Aug;76(4):541-7
1383132
Br J Cancer. 2002 Nov 4;87(10):1119-27
12402151
Cancer. 1993 Feb 15;71(4 Suppl):1602-12
8431896
Cancer. 1994 Jun 1;73(11):2808-17
7514955
Eur J Immunol. 1994 Jul;24(7):1597-603
7517877
Int Arch Allergy Appl Immunol. 1983;71(3):219-23
6602096
Immunol Commun. 1978;7(4):441-59
307530
Semin Oncol. 1998 Jun;25(3):356-60
9633848
Springer Semin Immunopathol. 1996;18(2):243-51
8908703
Immunol Rev. 1995 Jun;145:91-122
7590832
N Engl J Med. 2001 Apr 5;344(14):1058-66
11287977
J Clin Oncol. 1998 May;16(5):1861-8
9586902
Curr Top Microbiol Immunol. 1992;178:115-40
1424771
Springer Semin Immunopathol. 1994;15(4):369-96
8153873
Int J Cancer. 1997 Jan 6;70(1):14-25
8985085
Diagn Immunol. 1984;2(1):30-5
6209058
Lab Invest. 1994 Dec;71(6):820-7
7528832
Int J Cancer. 2002 Jan 1;97(1):72-81
11774246
Clin Cancer Res. 1997 Sep;3(9):1557-64
9815843
Anticancer Res. 2000 Mar-Apr;20(2B):1061-7
10810398
Am J Pathol. 1992 May;140(5):1039-43
1374587
Cancer Immunol Immunother. 1996 Mar;42(3):185-92
8640847
Cancer. 2000 Mar 15;88(6):1432-7
10717627
J Exp Med. 1993 May 1;177(5):1409-20
7683035
Am J Pathol. 1998 Sep;153(3):845-55
9736033
J Immunol. 1993 Nov 1;151(9):4941-9
7691959
Hepatology. 1985 Jul-Aug;5(4):634-7
4018735
J Hepatol. 1991 Jan;12(1):45-9
2007775
Br J Surg. 1996 Jan;83(1):6-14
8653366
Scand J Immunol. 2000 Jun;51(6):634-41
10849376
Acta Cytol. 1988 Nov-Dec;32(6):811-5
2974226
J Immunol. 2000 Jun 1;164(11):6075-81
10820293
Ann Hematol. 2002 Jul;81(7):405-6
12185515
Gynecol Oncol. 2001 Apr;81(1):71-6
11277653